Vical

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

•  Merger Transaction Expected to Close August 31, 2019

Vical Stockholders Approve Reverse Stock Split and Merger with Brickell

Investors need to pay close attention to Vical (VICL) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Vical (VICL) Stock

Vical announced a reverse merger with Brickell Biotech on June 3rd, 2019 which will require shareholder approval.

Rejecting The Vical-Brickell Reverse Merger Could Unlock 50% Upside

Vical (VICL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Vical Stock (VICL)